Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aeglea BioTherapeutics, Inc. (AGLE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.4414-0.0206 (-4.46%)
At close: 04:00PM EDT
0.4400 -0.00 (-0.32%)
After hours: 05:35PM EDT
Advertisement

Aeglea BioTherapeutics, Inc.

805 Las Cimas Parkway
Suite 100
Austin, TX 78746
United States
512 942 2935
https://www.aeglea.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees92

Key Executives

NameTitlePayExercisedYear Born
Dr. Leslie S. Sloan Ph.D.Chief Operating Officer626.94kN/A1971
Mr. Michael C. Hanley M.B.A.Chief Commercial Officer & Chief Bus. Officer577.42kN/A1973
Mr. James Paul Kastenmayer J.D., Ph.D.Interim CEO, Pres & Gen. CounselN/AN/A1972
Mr. Jonathan D. Alspaugh M.B.A.CFO & Principal Accounting OfficerN/AN/A1983
Ms. Cortney Caudill M.B.A.Sr. VP of Technical OperationsN/AN/AN/A
Joey PerroneVP of Fin. & Investor RelationsN/AN/AN/A
Dr. Kelly Boothe Ph.D.Sr. Director of Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Eugene SackettVP of HRN/AN/AN/A
Dr. Eric Bradford M.B.A., M.D., M.Sc.Chief Devel. OfficerN/AN/AN/A
Dr. Josie Gayton Ph.D.Sr. VP of Program Strategy, Operations & Chief of StaffN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Corporate Governance

Aeglea BioTherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement